

Application Number 10/574048  
 Response to Office Action dated 12/10/2007


RECEIVED  
 CENTRAL FAX CENTER  
 FEB 28 2008

Amendments to the Claims:


This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Original) A compound represented by Formula (I):



wherein R is a cyclic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; X is a bond or a divalent chain hydrocarbon group which may be substituted; X' is a bond or  $-\text{N}(\text{R}^5)-$  (wherein  $\text{R}^5$  is a hydrogen atom, a hydrocarbon group which may be substituted, an esterified or amidated carboxyl group, or an acyl group); Y is a divalent hydrocarbon group which may be substituted; Y' is a bond or  $-\text{C}(=\text{O})-$ ; ring A is a nitrogen-containing heterocycle which may be substituted;  $\text{Z}^1$  and  $\text{Z}^3$  are each independently a bond or a divalent chain hydrocarbon group which may be substituted;  $\text{Z}^2$  is a bond or  $-\text{N}(\text{R}^6)-$  (wherein  $\text{R}^6$  is a hydrogen atom, a hydrocarbon group which may be substituted, or an acyl group); B is a group represented by the formula:



(wherein  $\text{R}^1$  and  $\text{R}^2$  are each independently a hydrogen atom, a halogen atom, a hydrocarbon group which may be substituted, an alkoxy group which may be substituted, a carboxyl group which may be esterified or amidated, an acyl group, or an amino group which may be substituted;  $\text{R}^3$  is a hydrogen atom, a hydrocarbon group which may be

Application Number 10/574048  
Response to Office Action dated 12/10/2007

substituted, a carboxyl group which may be esterified or amidated, or an acyl group; R<sup>4</sup> is a hydrocarbon group which may be substituted; and R<sup>2</sup> and R<sup>1</sup> or R<sup>4</sup>, and R<sup>3</sup> and R<sup>4</sup> may be respectively bonded to each other to form a ring which may be substituted); R<sup>6</sup> and R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> or R<sup>4</sup> may be bonded to each other to form a ring which may be substituted; and a is 0, 1 or 2,

or a salt thereof.

2. (Cancelled)

3. (Original) The compound according to claim 1, wherein R is an aryl group which may be substituted with a substituent selected from a halogen atom, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, amino which may be substituted, nitro, cyano, amidino which may be substituted, and carboxyl which may be esterified or amidated.

4. (Original) The compound according to claim 1, wherein R is a heterocyclic group which may be substituted with a substituent selected from a halogen atom, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, amino which may be substituted, nitro, cyano, amidino which may be substituted, and carboxyl which may be esterified or amidated.

5. (Original) The compound according to claim 1, wherein R is naphthyl which may be substituted with a halogen atom.

6. (Original) The compound according to claim 1, wherein X is a bond, X' is a bond, Y is C<sub>1-3</sub> alkylene which may be substituted, and Y' is -C(=O)-.

7. (Original) The compound according to claim 6, wherein Y is C<sub>1-3</sub> alkylene substituted with a hydroxyl group.

8. (Original) The compound according to claim 1, wherein Z<sup>1</sup> and Z<sup>2</sup> are each a bond, and Z<sup>3</sup> is C<sub>1-3</sub> alkylene which may be substituted.

9. (Original) The compound according to claim 1, wherein ring A is a piperazine ring which may be substituted or a piperidine ring which may be substituted.

10. (Original) The compound according to claim 1, wherein ring A is a ring represented by the formula:



wherein ring A' may be further substituted,

Application Number 10/574048  
Response to Office Action dated 12/10/2007

or the formula:



wherein ring A" may be further substituted.

11. (Original) The compound according to claim 1, wherein R<sup>5</sup> is a hydrogen atom.
12. (Original) The compound according to claim 1, wherein a is 2.
13. (Currently amended) A compound selected from the group consisting of N-(4-((4-(3-((6-chloro-2-naphthyl)sulfonyl)propanoyl)-1-piperazinyl)methyl)-3-methyl-1,3-thiazol-2(3H)-ylidene)-N-methylamine, 4-((4-(3-((6-chloro-2-naphthyl)sulfonyl)propanoyl)-1-piperazinyl)methyl)-3-methyl-1,3-thiazol-2(3H)-imine, N-(5-((1-(3-((6-chloro-2-naphthyl)sulfonyl)propanoyl)-4-piperidinyl)methyl)-3-methyl-1,3-thiazol-2(3H)-ylidene)-N-methylamine, 5-(1-(3-((6-chloro-2-naphthyl)sulfonyl)propanoyl)-4-piperidinyl)-3-methyl-1,3-thiazol-2(3H)-imine, and 2-(2-((1-(3-((6-chloro-2-naphthyl)sulfonyl)propanoyl)-4-piperidinyl)imino)-1,3-thiazol-3(2H)-yl)ethanol, or a salt thereof or a prodrug thereof.
14. (Canceled)
15. (Currently Amended) A pharmaceutical composition comprising the compound according to claim 1 or 2.
16. (Original) The pharmaceutical composition according to claim 15, which is an anticoagulant.
17. (Original) The pharmaceutical composition according to claim 15, which is an activated blood coagulation factor X inhibitor.
18. (Currently amended) The pharmaceutical composition according to claim 15, which is a medicament for preventing or treating ~~myocardial infarction, cerebral infarction, deep vein thrombosis, pulmonary thromboembolism or atherosclerotic obliterans.~~
19. (Currently amended) The pharmaceutical composition according to claim 15, which is a medicament for preventing or treating economy-class syndrome, or treating thromboembolism during and post operation of hip replacement surgery, or the secondary onset of deep vein thrombosis.

Application Number 10/574048  
Response to Office Action dated 12/10/2007

20. (Canceled)

21. (Canceled)

22. (Canceled)

23. (Canceled)

24. (Canceled)

25. (Canceled)